The main objective of the application is to develop early diagnosis of cancer, thereby increasing the chances of patients recovering and reducing the costs of treatment related to cancers. In addition to the identification of biomarkers, laboratories with significant research potential in the consortium demonstrate the importance of biomarkers in model systems and explore the potential of individualised cancer therapies based on biomarkers. The above objectives are achieved by developing tumour diagnostic kits and technologies that are suitable for analysis of biopsies, surgical tumour samples and serum samples obtained by simple blood sampling. Not only in hospital, but also at outpatient level. In the course of the R & D activity, the Consortium develops and consolidates databases of tumour banks that are already being built up in accordance with international standards and state-of-the-art research needs and complements them with research and clinical results that significantly support pathologists, oncologists and surgeons using advanced image analysis algorithms. The Consortium will demonstrate the strength and impact of the resulting new technology by creating a diagnostic kit based on a new non-invasive sampling procedure in which the use of tumour bank samples identified by the established database plays a significant role. Based on the results of theoretical and professional research, we create diagnostic technology (diagnostic kit) and medical support IT system. In the course of our molecular tumour diagnostic development, our goal is to detect from blood sampling in a cost-effective way, if there is a tumour lesion in the body, which provides information for the selection of the most effective targeted therapy. During the project, tumour biomarkers and their patterns are identified by molecular and bioinformatics analysis of tumour cell lines, tumour and blood serum samples. The tumour bank and the user-friendly IT system are of central importance, which will propose biomarkers to be tested on the basis of the results of databases. This information is based on the activities of the first subtasks, which examines the value of each biomarker using molecular approaches and uses model systems to determine whether they contribute to tumour formation and determine their diagnostic value for targeted therapy. The identified biomarkers are also compared to tumour databases (constructing the diagnostic panel recommended for serum diagnostics. We continuously integrate new markers and biomarker patterns with diagnostic value to be identified in the development of kites suitable for diagnosis of tumour markers from serum. The development of the medical support and decision-making system is based on an algorithm processing the new biomarker patterns and the data obtained during the application of the developed serum diagnostic kit into the bioinformatics system created during the last sub-task, which assists in the selection of the most effective therapies of tumours characterised by different pathological and molecular biomarkers. It follows from the above that the technical tasks of the planned R & D project will be fully interdependent and will progress with the continuous integration of each other’s partial results. For the full implementation of the project, we plan to carry out the tasks specified in the task specifications. A medical support module will be part of the system to be developed. This module allows registered and logged-in doctors to help you choose the treatment method based on stored and analysed data (biomarkers). The project will lead to the following concrete implementations: — a state-of-the-art bioinformatics system will be available, which can be used in a user-friendly way for tumour bank recording of patient samples characterised by pathological and molecular biological methods and for complex analysis of patient samples, including information stored in other databases. — for tumour therapy, a medical support and decision-making system is established. — sensitive blood serum tumor diagnostic technology and commercially available diagnostic kit will be developed. — our development opens up the possibility of introducing a modern cancer diagnostic service, which determines the presence of the tumour from simple blood sampling and helps to determine the correct treatment and prognosis and monitor the progression of the tumour. Enterprise plans to implement the tender at its new site in Mórahalom, which is a suitable venue for several aspects: office building with offices and labs; our company’s premises operate in an office environment, which is suitable for research; ensure close cooperation with close consortium partners; the necessary IT infrastructure can be implemented under appropriate conditions. Hiperon Genetics Ltd. site level in Mórahalm